Rice Hall James & Associates’s Verona Pharma VRNA Stock Holding History

Rice Hall James & Associates’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,748	Closed	-$4.88M	–	255
2025 Q3	$4.88M	Sell	45,748 -562,248	-92%	-$58.7M	0.27%	91
2025 Q2	$57.5M	Sell	607,996 -215,016	-26%	-$15.9M	3.1%	2
2025 Q1	$52.3M	Sell	823,012 -131,604	-14%	-$7.87M	3.07%	2
2024 Q4	$44.3M	Sell	954,616 -30,460	-3%	-$1.14M	2.43%	6
2024 Q3	$28.3M	Buy	985,076 +45,500	+5%	+$1.12M	1.53%	16
2024 Q2	$13.6M	Buy	939,576 +263,819	+39%	+$3.85M	0.82%	31
2024 Q1	$10.9M	Buy	675,757 +206,828	+44%	+$3.58M	0.62%	47
2023 Q4	$9.32M	Buy	468,929 +443,055	+1,712%	+$6.54M	0.54%	49
2023 Q3	$422K	Buy	+25,874	New	+$498K	0.03%	246

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rice Hall James & Associates's VRNA Position: Q4 2025 in Review

Rice Hall James & Associates sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 45,748 shares — an estimated $4.88M sold.

Rice Hall James & Associates first reported a position in VRNA in Q3 2023 and held it in 9 quarters. The position peaked at $57.5M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Rice Hall James & Associates reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Rice Hall James & Associates sold 45,748 Verona Pharma shares in Q4 2025, an estimated $4.88M.
Rice Hall James & Associates first reported a position in Verona Pharma in Q3 2023 and held it in 9 quarters.
Rice Hall James & Associates's Verona Pharma position peaked at $57.5M in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Rice Hall James & Associates's 13F filing for Q4 2025, filed 17 Feb 2026.